Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort
Abstract Background The mTOR inhibitor Sirolimus was shown to improve symptoms in patients with slow-flow vascular malformations, but long-term continuous use is limited by cumulative toxicity. A personalized approach with intermittent regimens may offer similar efficacy with fewer adverse effects (...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-12-01
|
| Seri Bilgileri: | Orphanet Journal of Rare Diseases |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s13023-025-04151-y |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|